ArticleClinical diabetes : a publication of the American Diabetes Association2015
Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin.
Article in Clinical diabetes : a publication of the American Diabetes Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of the Replacement of Glycaemic Carbohydrates With Galacto-Oligosaccharide (GOS) Supplementation on Postprandial Glycaemic Response in Healthy Adults
Evaluation of Boiled Water Extracts of Legumes Seed Coats for Alpha Amylase and Alpha Glucosidase Activity: Formulation of Anti- Diabetic Nutraceuticals
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: A systematic review and meta-analysis.Journal of diabetes investigation · 2021Pooled it
- Intra-Islet Paracrine Regulation of Glucagon Secretion During Hypoglycemia, Euglycemia, and Hyperglycemia.Annals of the New York Academy of Sciences · 2026Review
- Correlation Analysis Between Obesity Index and Glycosylated Hemoglobin Level in Type 2 Diabetes Patients: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Review
- In Vitro Antioxidant Potential, Antidiabetic Activities, and GC-MS Analysis of Lipid Extracts ofBiotech (Basel (Switzerland)) · 2025Article
- Synthesis of modified Schiff base appended 1,2,4-triazole hybrids scaffolds: elucidating theZeitschrift fur Naturforschung. C, Journal of biosciences · 2025Article
- Revolutionizing Diabetes Care: The Role of Marine Bioactive Compounds and Microorganisms.Cell biochemistry and biophysics · 2025Review
- Diabetes Warriors from Heart Wood: Unveiling Dalbergin and Isoliquiritigenin from Dalbergia latifolia as Potential Antidiabetic Agents in-vitro and in-vivo.Cell biochemistry and biophysics · 2024Article
- Understanding suboptimal insulin use in type 1 and 2 diabetes: a cross-sectional survey of healthcare providers who treat people with diabetes.BMC primary care · 2024Article
- A Review on Indole-triazole Molecular Hybrids as a Leading Edge in Drug Discovery: Current Landscape and Future Perspectives.Current topics in medicinal chemistry · 2024Review
- Simultaneous Determination of Glibenclamide and Silymarin Released from Chitosan Microparticles by HPLC-ESI-MS Technique: Method Development and Validation.Pharmaceutics · 2022Article
- Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach.Cell and tissue research · 2021Review
- Antidiabetic Potential of Marine Brown Algae-a Mini Review.Journal of diabetes research · 2020Review
- Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter.Therapeutic advances in endocrinology and metabolism · 2018Review
- Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes.Experimental and therapeutic medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Brief For patients with type 2 diabetes who require add-on therapy to metformin plus basal insulin, GLP-1 receptor agonists may be a favorable option because they effectively manage postprandial glucose, reduce body weight, and have an overall favorable safety profile compared to other agents. Given the wide range of treatment combinations available for type 2 diabetes management, health professionals must partner with patients to determine the best choices based on patients' individual lifestyle, resources, and treatment goals.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.